178 results about "Serological assay" patented technology

Immunological assays for several biological markers for thyroid disorders in a biological sample are performed in a single test with a combination of sandwich-type, sequential competitive, and serological assays by the use of particles classified into groups that are distinguishable by flow cytometry, one group for the assay of each marker. Each group of particles is coated with a different immunological binding member, and coating densities, co-coating materials, and special buffer solutions are used to adjust for differences in the sensitivities and dynamic ranges of each of the markers in the typical sample.

The invention relates to the medical field of immunoassay, more specially, the invention provides a chemiluminescent immunoassay detection kit for des-gamma-carboxyand-prothrombin (DCP) microporosity plate and a preparation method thereof, and realizes the rapid, sensitive and high-specificity serological detection of DCP with the one step chemiluminescent immunoassay method. The kit of the invention has the advantages of simplicity, convenience, rapidness, sensitivity, stability and the like, eliminates the interference of the prothrombin analogues and the serum cellulose and the analogues thereof, and has the advantage of high specificity.

The invention relates to a biologically safe Africa swine fever antigen multifactorial serum for ELISA (enzyme-linked immuno sorbent assay) diagnosis. A technical scheme adopted in the invention includes: adopting gene-expressed structural protein P72, K205R, P54, and A104R, conducting chemical purification, carrying out coating with a Freund's incomplete adjuvant, performing intramuscular immunization on laboratory swine in three batches, collecting swine blood after one month, separating serum, implementing serological testing, and conducting subpackaging and preservation. The serum is subpackaged into ELISA kits to undergo test according to conventional ELISA test methods.

The invention relates to the medical field of immunoassay, more specially, the invention provides a chemiluminescent immunoassay detection kit for phosphatidylinositol proteoglycan-3(GPC-3) and a preparation method thereof, and realizes the simultaneous serological detection of GPC-3 N terminal and C-terminal protein with the chemiluminescent immunoassay method. The kit has the advantages of simple sampling, convenient detection and accurate and specific technical method. The invention adopts a biotin-strapavidin system to coat antibodies and improve the efficiency of antibody coating and the linear range of detection as well as sensitivity, and can be conveniently used for the tracing observation of early diagnosis or treatment effect for primary carcinoma of liver.

The invention discloses an ELISA detection method and a kit of blue-tongue virus antigen. The detection method uses the monoclonal antibody of anti-blue-tongue virus VP7 protein as dual-anti sandwich ELISA detection method of a coating and enzyme-marked antibody; and the kit comprises the monoclonal antibody of the anti-blue-tongue virus VP7 protein of the coating and enzyme-marked antibody. The kit and the detection method can be used for detecting the blue-tongue virus antigen, have higher specificity and sensitiveness, can be used in large-scale forserological detection, is suitable for epidemiological investigation and has wide application prospect.

Immunological assays for several biological markers for thyroid disorders in a biological sample are performed in a single test with a combination of sandwich-type, sequential competitive, and serological assays by the use of particles classified into groups that are distinguishable by flow cytometry, one group for the assay of each marker. Each group of particles is coated with a different immunological binding member, and coating densities, co-coating materials, and special buffer solutions are used to adjust for differences in the sensitivities and dynamic ranges of each of the markers in the typical sample.

The invention relates to enterovirus 71 type specific recombinant protein antigen and application thereof. The amino acid sequence is shown as SEQIDNO. 1; and the nucleotide sequence is shown as SEQIDNO. 2. The recombinant protein can be applied in preparation of monoclonal antibodies and polyclonal antibodies as well as detection of enterovirus 71 type specific antibodies. The invention provides a novel diagnostic antigen for serological detection of enterovirus 71 type infection. Experiments show that the enterovirus 71 type specific recombinant protein antigen has good sensitivity and specificity, can be identified by human serum after the enterovirus 71 type infection and inactivated full-virus immune serum of animals, can be applied in serological diagnosis of the enterovirus 71 type infection, and can also be applied in vaccine development and evaluation of immune effects in use. Compared with the full-virus particles as diagnostic antigens, the specific protein antigen can be prepared easily, and the cost of kit preparation is reduced.

The invention discloses a multi-drug resistance tuberculosis diagnosing marker set and application thereof. Sequences of multi-drug resistance tuberculosis diagnosing markers correspond to SEQ:ID:NO:1 to SEQ:ID:NO:8. The multi-drug resistance tuberculosis diagnosing markers are originated from 8 antigens of tuberculosis mycobacteria and used for judging whether a tested the optimal working point of protein combinations for diagnosing multi-drug resistance tuberculosis, the specificity is 80.4%, and the sensibility is 80%, wherein the specificity and the sensibility are both higher than indexes in diagnosis of multi-drug resistance tuberculosis in the prior art. In addition, in the technology, a serological test is adopted, samples are easy to obtain, and the multi-drug resistance tuberculosis diagnosing marker set is suitable for diagnosis of various kinds of suspicious multi-drug resistance tuberculosis including multi-drug resistance tuberculosis and extrapulmonary tubereulosis.

Immunological assays for several biological markers for thyroid disorders in a biological sample are performed in a single test with a combination of sandwich-type, sequential competitive, and serological assays by the use of particles classified into groups that are distinguishable by flow cytometry, one group for the assay of each marker. Each group of particles is coated with a different immunological binding member, and coating densities, co-coating materials, and special buffer solutions are used to adjust for differences in the sensitivities and dynamic ranges of each of the markers in the typical sample.

The invention provides an automatic blood group serology detection method and an automatic detection system for realizing the method. The method provided by the invention is convenient and effective, controllably improves the suspension effect of micro liquid and satisfies the operation requirements of blood immune reaction, so that results are more reliable and accurate; an adopted test tube luminous flux detection method is the obtained most widely-used method, can quickly judge experimental results and is high in accuracy rate, high in detection rate of weak agglutination and better in sensitivity. The detection system provided by the invention can quickly judge the experimental results through close cooperation of all parts and is high in accuracy rate, high in detection rate of weak agglutination and better in sensitivity; particularly, a bead adding device obtains a good effect and is high in degree of automation, accurate and quick in bead adding action, so that the vibration intensity of an existing oscillating mechanism is greatly reduced, the suspension effect of the micro liquid is improved, and the operation requirements of the blood immune reaction is satisfied.

The invention discloses a method for serologically detecting Matrix metalloproteinase 11 (MMP11) and the application thereof. The gene chip technology and the bioinformatics method are adopted to obtain stomach cancer gene expression spectra, and by taking the MMP11 gene for example, the expression characteristics of the gene in the tumor cell lines and tissues are verified at the levels of mRNA and protein. At the same time, a detection kit for the MMP11serum is established by utilizing the technique of the enzyme linked immuno sorbent assay (ELISA), and the expression level of the MMP11 protein in the serum of stomach cancer patients is detected. The level of the MMP11 protein in the serum of stomach cancer patients is obviously higher than that of a non-cancer comparison group (p is lower than 0.001), and the same tendency is also found in the breast cancer, the colon cancer/rectum cancer and the lung cancer. In the serum detection to the stomach cancer patients, the sensitivity of the MMP11 is higher than that of a tumor molecule marker such as CEA, CA199, CA72.4, CA242, etc., and MMP11 and CA199 have good correlation (p is equal to 0.017). Through the analysis of the clinic pathological data, the level of the serum MMP11 has the obvious correlation (p is equal to 0.009) with the cancerometastasis state of the stomach cancer patients. The MMP11 is possible to become a novel tumor serum marker for the diagnosis and the prognostic judgement of the tumors.

The invention discloses a stomach cancer serological detection and identification kit and a method. The stomach cancer serological detection and identification kit is prepared from a cel-miR-39-5p fragment, a primer, an exosome isolating reagent, an exosome miRNA (Micro Ribonucleic Acid) extracting reagent, a reverse transcription reagent and a real-time fluorescent quantitative PCR (Polymerase Chain Reaction) reagent, wherein the primer comprises a cel-miR-39-5p internal reference primer, an hsa-miR-375 primer, an hsa-miR-590-5p primer, an hsa-miR-19b-3p primer, an hsa-miR-100-5p primer and an hsa-miR-16 primer. When any results of detecting stomach cancer CA (Carbohydrate Antigen)19-9, CA24-2 and CEA (Carcino Embryonie Antigen) of a patient by using serum are positive, and the stomach cancer serological detection and identification kit provided by the invention is then used for carrying out aided detection, false positive results of serological detection can be effectively removed, so that huge mental stress and property loss brought to the patient can be avoided; meanwhile, aiming at the situation that when the results of detecting the stomach cancer CA19-9, CA24-2 and CEA of the patient by using the sera are negative, and the stomach cancer serological detection and identification kit provided by the invention is then used for carrying out the aided detection,, the false negative results of the serological detection can be effectively found, so that the life of the patient can be rescued in time.

The invention discloses an LAMP-based visual fluorogenic and chromogenic genetic testing method for microorganisms, which relates to a genetic testing method for microorganisms. The testing method includes the following steps: (1) buffered peptone water (BPW) is used for culturing a sample to be tested according to a national standard method for 4 hours; (2) a water boiling method is used for extracting DNA (deoxyribonucleic acid) from the sample to be tested; (3) the DNA is added into an LAMP reaction system, and the temperature of 65 DEG C is kept for 1 hour; (4) by means of comparison with a control group, the result of the sample to be tested is observed with naked eyes, and qualitative analysis is carried out on the sample. Compared with the conventional culture method, the genetic testing method has the advantages that: testing is rapid, only taking 5 hours, and plus the extraction of the sample DNA, testing takes less than 6 hours in total; the specificity is good, and the sensitivity is high; the steps are simple, and the repeatability is high; and a plurality of samples can be tested at the same time. The genetic testing method can qualitatively test microorganisms, and can take the place of the conventional culture method and the serological testing method which are used up to now.

The invention belongs to the field of immunodetection and relates to a detection kit for distinguishing cow pathogenic mycobacteria infection from non-pathogenic mycobacteria infection and a method thereof. The detection reagent comprises combined fusion protein rE6-M63-H70 used as a specific stimulation origin, the combined fusion protein can effectively stimulate sensitized peripheral blood lymphocyte cultured in vitro to release Gamma-interferon (IFN-Gamma) at a high level. The cow IFN-Gamma release test established by using the detection reagent rE6-M63-H70 combined fusion protein as the stimulation origin overcomes the insufficiencies of serology detection method and the IFN-Gamma release test with PPD as the stimulation origin, thus enjoying very high sensitivity and specificity and distinguishing cow pathogenic mycobacteria ( such as mycobacterium bovis) infection from non-pathogenic mycobacteria (such as mycobacterium avium or non-pathogenic mycobacteria) infection and even distinguishing the cow pathogenic mycobacteria infection from BGG immunity; therefore, the detection kit and the method of the invention can be effectively used to detect the clinical cow pathogenic mycobacteria infection.

The invention provides a primer and a method for detecting HTLV (human T-lymphotropic virus)-I and HTLV-II proviruses. The primer comprises a specific primer and a probe for detecting an HTLV-I provirus and a specific primer and a probe for detecting an HTLV-II provirus, the two primers and the two probes are added in the same PCR (polymerase chain reaction) pipe according to a reasonable concentration ratio, and a sample is detected by means of optimized Real-time PCR reaction conditions. The detection method can be used for detecting whether HTLV infection exists before serological changes, thereby greatly shortening the window phase; meanwhile, compared with a conventional serological detection method, the detection method has the advantages of short detection period, high specificity, high accuracy, high sensitivity, little dependence on the conditions, low pollution risk and the like. The detection result is beneficial to monitor the change of the carrying capacity of the HTLV provirus of a patient and limit the propagation of the HTLV virus.

The invention provides a dengue virus serology early diagnosis reagent, in particular, EIII structural domains of dengue viruses 1, 2, 3 and 4 are serially connected to obtain a recombinant fusion protein rEIII used for serodiagnosis of the dengue virus infection. In addition, the invention also provides an early diagnosis agent kit suitable for the dengue virus infection. The invention provides a new idea for the serodiagnosis of the dengue virus infection. The dengue virus infection can be effectively diagnosed by using the diagnosis reagent, especially, the Mac-ELISA (Enzyme Linked Immunosorbent Assay) diagnosis agent kit can be effectively used for the early serodiagnosis of the dengue virus infection. The diagnosis reagent has the advantages of better specificity and sensitivity and simple operation, and is suitable for being widely popularized and used.

A universal and differential assay kit for the detection of antibodies to swine influenza virus (SIV) in a biological sample comprising SIV non-structural 1 (NS1) protein and SIV nucleoprotein (NP); a universal and differential assay method for detecting antibodies to SIV in a biological sample comprising assaying the biological sample for the presence of an antibody to SIV NS1 protein and an antibody to SIV NP; primers; and fusion proteins.

The invention discloses a polypeptide enzyme-linked immunosorbent assay kit for detecting a novel coronavirus surface spinous process protein S unique specific antibody. The kit comprises an elisa plate coated with SARS-CoV2 surface spinous process protein S unique specificity dominant linear B cell antigen polypeptide, a sample diluent, negative control serum, positive control serum, a horse radish peroxidase labeled antibody, a concentrated washing solution, an enzyme substrate solution and a stop solution. The kit disclosed by the invention is high in specificity and good in repeatability,can be simply and conveniently used for detecting the novel coronavirus unique antibody, reduces false positive, can be used for large-scale serological detection and epidemiological investigation, and evaluates the infection condition of the novel coronavirus.

The invention provides a test kit and a preparing method thereof for rubella IgG antibody detecting by integrating chemiluminescence immunoassay with capture method. The test kit is composed of positive and negative reference substance, a micro-perforated plate which is coated by antihuman IgM u link, neutralizing antigen, sample diluent, condensed washing liquid, alkaline phosphatase labeled monoclonal antibody, and chemiluminescence zymolyte. The preparing method of the test kit includes: 1) the positive and negative reference substance is prepared; 2) the micro-perforated plate is coated by the antihuman IgM u link; 3) the neutralizing antigen is prepared; 4) the sample diluent is prepared; 5) the condensed washing liquid is prepared; 6) the rubella monoclonal antibody is labeled by the alkaline phosphatase; 7) the chemiluminescence zymolyte is prepared; 8) all components above can be filled and packed through separate packing and finished product can be made after assembly. The invention has the advantages that the sensitivity is high and the specificity is strong, thereby providing serology detection, epidemiology investigation and clinical diagnose with a reliable scientific diagnosing evidence which is helpful in eugenics.

The invention relates to an indirect ELISA kit for detecting a porcine transfusion transmitted virus 2 (TTV2) antibody and belongs to the field of biotechnology. The invention comprises antigen recombinant protein preparation, indirect ELISA establishing, and use of determination standard and clinical serological test. Through pcoldI prokaryotic expression vectors, a gene engineering bacterium pcoldI-ORF1 for expression of a porcine TTV2ORF1 truncated protein is constructed and the expressed antigen recombinant protein is purified and is used as an antigen so that an indirect ELISA detection method is established. The indirect ELISA detection method is used for detecting a TTV2 antibody level of porcine serum, has good repeatability and high singularity, can be used for porcine TTV2 serology investigation and is a fast and simple serological test method for prevention, treatment and prevalence state control of porcine transfusion transmitted diseases. The indirect ELISA detection method utilizes the porcine TTV2ORF1 recombinant protein to detect the porcine TTV2 antibody first in China.

The invention relates to ANGPTL4 as a marker of liver cancer metastasis by serological detection and an application thereof. Specifically, the invention provides an application of angiopoietin-like protein 4(ANGPTL4 protein) in (a) the preparation of a diagnostic reagent or kit for the detection of liver cancer metastasis and (b) the preparation of a diagnostic reagent or kit for serological detection of liver cancer. The invention also provides a related detection kit. The invention also provides a method for inhibiting hepatoma cell metastasis by the use of an antagonist of the ANGPTL 4 protein.

The invention provides screening and application of active tuberculosis diagnosis molecules. In particular, the invention discloses high throughput screening of mycobacterium tuberculosis's important antigens and application thereof in active tuberculosis diagnosis. Based on a high throughput functional protein screening technology of GST fusion expression, 92 positive antigens recognizable by tuberculosis patients' serum are screened out, wherein 14 antigens present strongly positive reaction. Active tuberculosis serologic detection shows that the positive antigens have high sensitivity and specificity in detection of active tuberculosis. Specifically, TBGP1, TBGP2, TBGP3, TBGP4, TBGP5 and TBGP6 6 proteins form an antigen combination for tuberculosis serologic detection, and laboratory verification shows that the combination has high sensitivity and specificity in detection of mycobacterium tuberculosis, and has application value in tuberculosis diagnosis and monitoring.

The invention relates to a targeted database creation kit for 43 pathogens. The pathogens comprise bacteria, viruses, fungi and protozoa. Targeted detection primer sequences of the pathogens are shownas SEQ ID NO. 1 to 86. According to the kit, targeted database creation can be performed on pathogen nucleic acids in an early infection stage for rapid diagnosis of the pathogens after next-generation sequencing, and directions are provided for subsequent pathogen isolation and identification, serologic detection, clinical diagnosis and symptomatic treatment.

The invention discloses a kit for detecting Golgi protein 73 by a magnetic particle chemiluminescence method and a preparation method thereof, and belongs to the technical field of immunoassay. The kit comprises a streptavidin-coated magnetic particle suspension solution, a biotinylation labeled GP73 antibody solution, an alkaline phosphatase labeled Golgi protein 73 antibody solution, a calibrator, a washing solution and a substrate solution. The problems that pathological specimens need to be obtained in histological detection, the GP73 state of a patient who does not obtain cancer tissue pathology cannot be judged, and repeated detection is difficult are solved. Serological detection has the characteristics of convenience, repeatable measurement, quantification, objectivity, real-time detection and the like. The method has the advantages that the reaction time is short, radioactive contamination is avoided, the experimental operation process is simplified, the binding between the biotin and the streptavidin has extremely high affinity, and the reaction has high specificity. Therefore, non-specific interference is not increased while the sensitivity is improved.

The invention provides an evaluation system of anti-aging effect of autologous adipose-derived stem cell. The system comprises that serology detection is carried out on an individual re-transfused with adipose-derived stem cells a period after a re-transfusion; and the serology detection comprises one or more indexes selected from the group of vitamin D, high density lipoprotein, low density lipoprotein, hormothyrin, testosterone and estradiol. The evaluation system of the invention can objectively evaluate anti-aging effect of adipose derived stem cell and has advantages of accuracy, rapidness and thrift.